Physician profile
Chance M Benner
NPI 1184116436
$2,950.15
in general payments reported to CMS, 2019-2025
10 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.33 · 2022: $326 · 2024: $355 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,368 · Food and Beverage: $961 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,368.03 |
| Food and Beverage | $960.86 |
| Education | $229.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,431.51 | 2021-2025 | Corevalve Evolut R |
| Atricure, INC. | $670.10 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Atricure Cryoice Cryoablation System (Cryo2) |
| Edwards Lifesciences Corporation | $386.49 | 2024-2025 | Konect Resilia |
| La Jolla Pharmaceutical Company | $120.00 | 2022 | |
| Medical Device Business Services, INC. | $117.60 | 2024 | Evarrest |
| Silk Road Medical, INC. | $83.68 | 2022-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Abiomed | $65.64 | 2024-2025 | Impella |
| Intuitive Surgical, INC. | $31.58 | 2022 | |
| Davol INC. | $22.74 | 2021 | |
| Baxter Healthcare | $20.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chance Benner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.